QDEL1 * Stock Overview
Provides diagnostic testing solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
QuidelOrtho Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,154.00 |
| 52 Week High | US$1,154.00 |
| 52 Week Low | US$1,154.00 |
| Beta | 0.11 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -63.67% |
| 5 Year Change | n/a |
| Change since IPO | -66.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| QDEL1 * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how QDEL1 * performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how QDEL1 * performed against the MX Market.
Price Volatility
| QDEL1 * volatility | |
|---|---|
| QDEL1 * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: QDEL1 * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine QDEL1 *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 7,000 | Mike Iskra | www.quidelortho.com |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
QuidelOrtho Corporation Fundamentals Summary
| QDEL1 * fundamental statistics | |
|---|---|
| Market cap | Mex$51.80b |
| Earnings (TTM) | -Mex$171.89m |
| Revenue (TTM) | Mex$51.02b |
1.0x
P/S Ratio-301.4x
P/E RatioIs QDEL1 * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QDEL1 * income statement (TTM) | |
|---|---|
| Revenue | US$3.00b |
| Cost of Revenue | US$1.50b |
| Gross Profit | US$1.49b |
| Other Expenses | US$1.50b |
| Earnings | -US$10.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 49.85% |
| Net Profit Margin | -0.34% |
| Debt/Equity Ratio | 48.4% |
How did QDEL1 * perform over the long term?
See historical performance and comparison